(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of -6.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Cormedix's revenue in 2026 is $400,054,343.On average, 8 Wall Street analysts forecast CRMD's revenue for 2026 to be $26,623,433,730, with the lowest CRMD revenue forecast at $25,048,904,277, and the highest CRMD revenue forecast at $27,677,827,145. On average, 8 Wall Street analysts forecast CRMD's revenue for 2027 to be $22,949,531,674, with the lowest CRMD revenue forecast at $21,711,560,834, and the highest CRMD revenue forecast at $24,353,820,523.
In 2028, CRMD is forecast to generate $27,653,507,059 in revenue, with the lowest revenue forecast at $25,287,398,026 and the highest revenue forecast at $29,350,421,461.